Histogen, Inc. is a regenerative medicine company based on naturally-produced products from newborn fibroblasts grown in a proprietary bioreactor that mimics the embryonic environment. Histogen has developed a rich product portfolio from one core technology process that fulfills market needs without the use of embryonic stem cells or animal products.

The purpose and focus of the company is on the research, development, manufacturing and sales of products derived from the company's core technology. Using this proprietary tissue-engineering platform, the company has created products that offer unique commercialization opportunities ranging from research tools to biological products in various markets and segments of the biomedical industry.

History

Histogen, Inc. was founded in 2007 to develop products utilizing the proteins and growth factors produced by newborn fibroblasts, as well as continue vital research. Histogen is incorporated in the State of Delaware, with headquarters and research facility in San Diego, California.

Dr. Gail Naughton is a respected scientist with extensive experience in the field of tissue engineering. Naughton discovered the potential of proteins and growth factors produced by newborn fibroblasts for therapeutic and biomedical applications, and developed Histogen's unique technology process to create products based on these proteins. The technology is protected by two distinct patent families filed in the US and Europe.